BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A; SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-64. [PMID: 19144760 DOI: 10.1681/ASN.2008050482] [Cited by in Crossref: 163] [Cited by in F6Publishing: 63] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Barton M, Sorokin A. Endothelin and the glomerulus in chronic kidney disease. Semin Nephrol 2015;35:156-67. [PMID: 25966347 DOI: 10.1016/j.semnephrol.2015.02.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
2 Ritz E, Wenzel R. Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn. J Am Soc Nephrol 2010;21:392-4. [PMID: 20133487 DOI: 10.1681/ASN.2010010047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 2011;34 Suppl 2:S330-4. [PMID: 21525478 DOI: 10.2337/dc11-s242] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
4 Pollock DM. 2013 Dahl Lecture: American Heart Association council for high blood pressure research clarifying the physiology of endothelin. Hypertension 2014;63:e110-7. [PMID: 24614220 DOI: 10.1161/HYPERTENSIONAHA.114.02441] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; for the ASCEND Study Group. Avosentan for Overt Diabetic Nephropathy. JASN 2010;21:527-35. [DOI: 10.1681/asn.2009060593] [Cited by in Crossref: 298] [Cited by in F6Publishing: 133] [Article Influence: 24.8] [Reference Citation Analysis]
6 Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol 2014;10:325-46. [PMID: 24802062 DOI: 10.1038/nrneph.2014.74] [Cited by in Crossref: 118] [Cited by in F6Publishing: 103] [Article Influence: 14.8] [Reference Citation Analysis]
7 Samad MA, Kim UK, Kang JJ, Ke Q, Kang PM. Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner. PLoS One 2015;10:e0121664. [PMID: 25775254 DOI: 10.1371/journal.pone.0121664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Wang L, Jirka G, Rosenberg PB, Buckley AF, Gomez JA, Fields TA, Winn MP, Spurney RF. Gq signaling causes glomerular injury by activating TRPC6. J Clin Invest 2015;125:1913-26. [PMID: 25844902 DOI: 10.1172/JCI76767] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
9 Heerspink HJL, Law G, Psachoulia K, Connolly K, Whatling C, Ericsson H, Knöchel J, Lindstedt EL, MacPhee I. Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. Kidney Int Rep 2021;6:2803-10. [PMID: 34805632 DOI: 10.1016/j.ekir.2021.08.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ritz E, Zeng X. Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. Indian J Nephrol 2011;21:75-84. [PMID: 21769168 DOI: 10.4103/0971-4065.82122] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
11 Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010;56:942-9. [PMID: 20823379 DOI: 10.1161/HYPERTENSIONAHA.110.156570] [Cited by in Crossref: 83] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
12 Khan SS, Quaggin SE. Therapies on the Horizon for Diabetic Kidney Disease. Curr Diab Rep 2015;15:111. [PMID: 26458382 DOI: 10.1007/s11892-015-0685-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
13 Burnier M. Update on Endothelin Receptor Antagonists in Hypertension. Curr Hypertens Rep 2018;20:51. [PMID: 29779164 DOI: 10.1007/s11906-018-0848-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
14 Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL, Cherney DZI. The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. Endocr Rev 2020;41:bnz010. [PMID: 31633153 DOI: 10.1210/endrev/bnz010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
15 Pirklbauer M, Bernd M, Fuchs L, Staudinger P, Corazza U, Leierer J, Mayer G, Schramek H. Empagliflozin Inhibits Basal and IL-1β-Mediated MCP-1/CCL2 and Endothelin-1 Expression in Human Proximal Tubular Cells. Int J Mol Sci 2020;21:E8189. [PMID: 33139635 DOI: 10.3390/ijms21218189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Noone D, Licht C. Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options. Pediatr Nephrol 2014;29:779-92. [PMID: 23471475 DOI: 10.1007/s00467-013-2436-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
17 Zhou Z, Wan J, Hou X, Geng J, Li X, Bai X. MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy. Cell Death Dis 2017;8:e2658. [PMID: 28277542 DOI: 10.1038/cddis.2017.74] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
18 Lee SY, Kim SI, Choi ME. Therapeutic targets for treating fibrotic kidney diseases. Transl Res 2015;165:512-30. [PMID: 25176603 DOI: 10.1016/j.trsl.2014.07.010] [Cited by in Crossref: 92] [Cited by in F6Publishing: 90] [Article Influence: 11.5] [Reference Citation Analysis]
19 Bai S, Xiong X, Tang B, Ji T, Li X, Qu X, Li W. Exosomal circ_DLGAP4 promotes diabetic kidney disease progression by sponging miR-143 and targeting ERBB3/NF-κB/MMP-2 axis. Cell Death Dis 2020;11:1008. [PMID: 33230102 DOI: 10.1038/s41419-020-03169-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lim AKh. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361-381. [PMID: 25342915 DOI: 10.2147/ijnrd.s40172] [Cited by in Crossref: 217] [Cited by in F6Publishing: 96] [Article Influence: 27.1] [Reference Citation Analysis]
21 Ahmad N, Veerapalli H, Lankala CR, Castaneda EE, Aziz A, Rockferry AG, Hamid P. Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review. Cureus 2021;13:e19325. [PMID: 34909290 DOI: 10.7759/cureus.19325] [Reference Citation Analysis]
22 Ward F, Holian J, Murray PT. Drug therapies to delay the progression of chronic kidney disease. Clin Med (Lond) 2015;15:550-7. [PMID: 26621944 DOI: 10.7861/clinmedicine.15-6-550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
23 Ritz E. Drug of choice in the management of hypertension in diabetes and diabetic nephropathy: angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011;13:285-9. [PMID: 21466627 DOI: 10.1111/j.1751-7176.2011.00448.x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Chan EA, Buckley B, Farraj AK, Thompson LC. The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction. Pharmacol Ther 2016;165:63-78. [PMID: 27222357 DOI: 10.1016/j.pharmthera.2016.05.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
25 Chou JC, Rollins SD, Ye M, Batlle D, Fawzi AA. Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice. Invest Ophthalmol Vis Sci 2014;55:2516-25. [PMID: 24644048 DOI: 10.1167/iovs.13-13676] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
26 Cherney DZI, Bakris GL. Novel therapies for diabetic kidney disease. Kidney Int Suppl (2011) 2018;8:18-25. [PMID: 30675435 DOI: 10.1016/j.kisu.2017.10.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
27 Tampe D, Zeisberg M. Potential approaches to reverse or repair renal fibrosis. Nat Rev Nephrol 2014;10:226-37. [DOI: 10.1038/nrneph.2014.14] [Cited by in Crossref: 119] [Cited by in F6Publishing: 114] [Article Influence: 14.9] [Reference Citation Analysis]
28 Kittikulsuth W, Sullivan JC, Pollock DM. ET-1 actions in the kidney: evidence for sex differences. Br J Pharmacol 2013;168:318-26. [PMID: 22372527 DOI: 10.1111/j.1476-5381.2012.01922.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
29 Benigni A, Buelli S, Kohan DE. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. Pediatr Nephrol 2021;36:763-75. [PMID: 32185491 DOI: 10.1007/s00467-020-04518-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014;25:1083-93. [PMID: 24722445 DOI: 10.1681/ASN.2013080830] [Cited by in Crossref: 148] [Cited by in F6Publishing: 78] [Article Influence: 18.5] [Reference Citation Analysis]
31 Anguiano L, Riera M, Pascual J, Soler MJ. Endothelin Blockade in Diabetic Kidney Disease. J Clin Med 2015;4:1171-92. [PMID: 26239552 DOI: 10.3390/jcm4061171] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
32 Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22:763-72. [PMID: 21372210 DOI: 10.1681/ASN.2010080869] [Cited by in Crossref: 159] [Cited by in F6Publishing: 74] [Article Influence: 14.5] [Reference Citation Analysis]
33 Zhang L, Xue S, Hou J, Chen G, Xu ZG. Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review. World J Diabetes 2020; 11(11): 553-566 [PMID: 33269066 DOI: 10.4239/wjd.v11.i11.553] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia 2011;54:979-88. [PMID: 21191784 DOI: 10.1007/s00125-010-2021-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
35 Johnson SA, Spurney RF. Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy. Am J Physiol Renal Physiol 2015;309:F807-20. [PMID: 26336162 DOI: 10.1152/ajprenal.00266.2015] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
36 Farrah TE, Anand A, Gallacher PJ, Kimmitt R, Carter E, Dear JW, Mills NL, Webb DJ, Dhaun N. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease. Hypertension 2019;74:323-30. [PMID: 31177906 DOI: 10.1161/HYPERTENSIONAHA.119.12919] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
37 Gohar EY, Giachini FR, Pollock DM, Tostes RC. Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases. Life Sci 2016;159:20-9. [PMID: 26939577 DOI: 10.1016/j.lfs.2016.02.093] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
38 Sarafidis PA, Lasaridis AN. Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy. Nat Rev Nephrol. 2010;6:447-449. [PMID: 20664627 DOI: 10.1038/nrneph.2010.86] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
39 Noone D, Licht C. An update on the pathomechanisms and future therapies of Alport syndrome. Pediatr Nephrol 2013;28:1025-36. [PMID: 22903660 DOI: 10.1007/s00467-012-2272-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
40 Gordon J, Kopp JB. Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv Chronic Kidney Dis 2011;18:300-11. [PMID: 21782136 DOI: 10.1053/j.ackd.2011.06.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
41 Watson AM, Li J, Schumacher C, de Gasparo M, Feng B, Thomas MC, Allen TJ, Cooper ME, Jandeleit-Dahm KA. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2010;53:192-203. [PMID: 19862499 DOI: 10.1007/s00125-009-1540-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
42 Kohan DE, Lambers Heerspink HJ, Coll B, Andress D, Brennan JJ, Kitzman DW, Correa-Rotter R, Makino H, Perkovic V, Hou FF. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clin J Am Soc Nephrol. 2015;10:1568-1574. [PMID: 26153128 DOI: 10.2215/cjn.00570115] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
43 Pichler RH, de Boer IH. Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease. Curr Diab Rep. 2010;10:297-305. [PMID: 20532701 DOI: 10.1007/s11892-010-0126-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
44 Buelli S, Rosanò L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, Perico L, Conti S, Rizzo P, Novelli R, Morigi M, Zoja C, Remuzzi G, Bagnato A, Benigni A. β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol 2014;25:523-33. [PMID: 24371298 DOI: 10.1681/ASN.2013040362] [Cited by in Crossref: 50] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
45 Kino J, Tsuji S, Kitao T, Akagawa Y, Yamanouchi S, Kimata T, Kaneko K. Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat. Pediatr Res 2018;83:1041-8. [PMID: 29360807 DOI: 10.1038/pr.2018.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Wang L, Chang JH, Paik SY, Tang Y, Eisner W, Spurney RF. Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. Mol Endocrinol 2011;25:1376-86. [PMID: 21622531 DOI: 10.1210/me.2011-0029] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
47 Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014;86:896-904. [PMID: 24805108 DOI: 10.1038/ki.2014.143] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 14.1] [Reference Citation Analysis]
48 Tan RJ, Zhou L, Zhou D, Lin L, Liu Y. Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy. PLoS One 2013;8:e79963. [PMID: 24265790 DOI: 10.1371/journal.pone.0079963] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
49 Schievink B, de Zeeuw D, Smink PA, Andress D, Brennan JJ, Coll B, Correa-Rotter R, Hou FF, Kohan D, Kitzman DW, Makino H, Parving HH, Perkovic V, Remuzzi G, Tobe S, Toto R, Hoekman J, Lambers Heerspink HJ. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. Eur J Prev Cardiol 2016;23:758-68. [PMID: 26229089 DOI: 10.1177/2047487315598709] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
50 Kohan DE, Pollock DM. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 2013;76:573-9. [PMID: 23228194 DOI: 10.1111/bcp.12064] [Cited by in Crossref: 24] [Cited by in F6Publishing: 45] [Article Influence: 3.0] [Reference Citation Analysis]
51 Hoekman J, Lambers Heerspink HJ, Viberti G, Green D, Mann JF, de Zeeuw D. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. Clin J Am Soc Nephrol 2014;9:490-8. [PMID: 24408122 DOI: 10.2215/CJN.07040713] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
52 Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis. 2013;7:13-24. [PMID: 24379690 DOI: 10.2147/ijnrd.s40522] [Cited by in Crossref: 5] [Cited by in F6Publishing: 33] [Article Influence: 0.6] [Reference Citation Analysis]
53 Baltatu OC, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA. Antidiuretic effects of the endothelin receptor antagonist avosentan. Front Physiol 2012;3:103. [PMID: 22529820 DOI: 10.3389/fphys.2012.00103] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
54 Heerspink HJ, de Zeeuw D. The kidney in type 2 diabetes therapy. Rev Diabet Stud 2011;8:392-402. [PMID: 22262076 DOI: 10.1900/RDS.2011.8.392] [Cited by in Crossref: 56] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
55 Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab 2018;20:1369-76. [PMID: 29405626 DOI: 10.1111/dom.13245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
56 Werth S, Lehnert H, Steinhoff J. [Diabetic nephropathy: current diagnostics and treatment]. Internist (Berl) 2015;56:513-9. [PMID: 25762007 DOI: 10.1007/s00108-014-3629-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010;19:134-9. [PMID: 20051851 DOI: 10.1097/MNH.0b013e328335f91f] [Cited by in Crossref: 78] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
58 Saleh MA, Sandoval RM, Rhodes GJ, Campos-Bilderback SB, Molitoris BA, Pollock DM. Chronic endothelin-1 infusion elevates glomerular sieving coefficient and proximal tubular albumin reuptake in the rat. Life Sci 2012;91:634-7. [PMID: 22727794 DOI: 10.1016/j.lfs.2012.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
59 Pan Y, Hu C, Chen PH, Gu YH, Qiao QY, Pan LH, Zhou DC, Gu HF, Fu SK, Jin HM. Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2017;73:267-78. [PMID: 27957707 DOI: 10.1007/s00228-016-2171-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Kasztan M, Fox BM, Speed JS, De Miguel C, Gohar EY, Townes TM, Kutlar A, Pollock JS, Pollock DM. Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice. J Am Soc Nephrol 2017;28:2443-58. [PMID: 28348063 DOI: 10.1681/ASN.2016070711] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
61 Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 2009;5:375-83. [PMID: 19455178 DOI: 10.1038/nrneph.2009.76] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
62 Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 2016;310:R877-84. [PMID: 27009050 DOI: 10.1152/ajpregu.00425.2015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
63 Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 2012; 3(1): 1-6 [PMID: 22253940 DOI: 10.4239/wjd.v3.i1.1] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 92] [Article Influence: 9.6] [Reference Citation Analysis]
64 Dounousi E, Duni A, Leivaditis K, Vaios V, Eleftheriadis T, Liakopoulos V. Improvements in the Management of Diabetic Nephropathy. Rev Diabet Stud 2015;12:119-33. [PMID: 26676665 DOI: 10.1900/RDS.2015.12.119] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 5.9] [Reference Citation Analysis]
65 Koomen JV, Stevens J, Mostafa NM, Parving HH, de Zeeuw D, Heerspink HJL. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. Diabetes Obes Metab 2018;20:2019-22. [PMID: 29603851 DOI: 10.1111/dom.13312] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
66 Pirklbauer M, Sallaberger S, Staudinger P, Corazza U, Leierer J, Mayer G, Schramek H. Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells. Int J Mol Sci 2021;22:5089. [PMID: 34064989 DOI: 10.3390/ijms22105089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]